Related Experiment Video

Updated: Sep 7, 2025

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.5K

YES1: A Novel Therapeutic Target and Biomarker in Cancer

Irati Garmendia1,2, Esther Redin1,2,3, Luis M Montuenga1,2,3

  • 1CIBERONC, ISCIII, Madrid, Spain.

Molecular Cancer Therapeutics
|June 22, 2022
PubMed

Insights

YES1, a key cancer-driving kinase, shows promise as a therapeutic target and biomarker. Inhibiting YES1 in tumors with high expression offers a potential new cancer treatment strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • YES1 is a nonreceptor tyrosine kinase in the SRC family of kinases (SFK).
  • YES1 overexpression drives cancer cell proliferation, survival, and invasiveness.
  • YES1 is amplified and overexpressed in numerous solid tumors, indicating its oncogenic role.

Purpose of the Study:

  • To review the structure, activation, and role of YES1 in cancer.
  • To evaluate YES1 as a therapeutic target, prognostic biomarker, and companion diagnostic.
  • To discuss the efficacy and challenges of SRC family kinase inhibitors in clinical trials.

Main Methods:

  • Literature review of YES1 function and inhibitors.
  • Analysis of preclinical data for YES1-specific inhibitors.
  • Examination of clinical trial data for SFK inhibitors.

Main Results:

  • YES1 plays a critical role in multiple cancer signaling pathways.
  • Novel YES1 inhibitors demonstrate significant antitumor effects in preclinical models.
  • Existing SFK inhibitors face challenges in clinical application due to toxicity and efficacy issues.

Conclusions:

  • YES1 is a promising therapeutic target and biomarker in cancer treatment.
  • Targeting YES1 in tumors with high expression presents a viable anti-cancer strategy.
  • Further research into YES1-specific inhibitors is warranted for clinical translation.

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.5K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.8K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K